CERO
NASDAQCERo Therapeutics Holdings Inc.
Price$0.10+0.00 (+0.00%)
2026-07-162026-10-16
News · 26 weeks210%
2026-04-192026-10-11
Mix490d
- SEC Filings2(50%)
- M&A1(25%)
- Other1(25%)
Latest news
25 items- PRSRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic MalignanciesSPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo Holdings"
- SECSEC Form 8-K filed by CERo Therapeutics Holdings Inc.8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRSRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic CancersNORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has purchased senior secured debt in CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo Holdings" and, together with CERo Therapeutics, "CERo"), an innovative cellular immunotherapy company advancing next generation engineered T cell therapeutics that employ phagocytic mechanisms. The investment is expected to provide CERo with additional capital to accelerate the advancement of its clinical programs.
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 25-NSE filed by CERo Therapeutics Holdings Inc.25-NSE - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentFifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced a clinical update from investigators participating in the ongoing Phase 1 CERTAIN-T clinical trial evaluating CER-1236 in hematologic malignancies. Patient five in the trial had multiple refractory acute myeloi
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 10-Q filed by CERo Therapeutics Holdings Inc.10-Q - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 TrialCompany to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has completed dosing and the 28-day dose-limiting toxicity ("DLT") assessment period for all three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 in hematologic malignancies. In the second cohort, patients received CER-1236 at a total dose o
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECAmendment: SEC Form 10-K/A filed by CERo Therapeutics Holdings Inc.10-K/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- INSIDERSEC Form 4 filed by Francois Eric4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 3 filed by new insider Francois Eric3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 10-K filed by CERo Therapeutics Holdings Inc.10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
CERO FAQ
6 questionsWhere does CERO stock trade?
CERo Therapeutics Holdings Inc. (CERO) is listed on NASDAQ.What sector and industry is CERO in?
CERo Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did CERo Therapeutics Holdings Inc. go public?
CERo Therapeutics Holdings Inc. (CERO) completed its IPO in 2021.What are analysts saying about CERO?
CERo Therapeutics Holdings Inc. has had 1 recent analyst action on file. The most recent action was from D. Boral Capital: Buy with a $3000.00 price target on 2025-06-23. Recent price targets cluster around $3000.00.What companies are similar to CERO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CERO side-by-side with any of them on Quantisnow.How can I track CERO on Quantisnow?
Quantisnow aggregates CERo Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERO to receive live email and push alerts on every new disclosure.